Pharmaceutical Companies Pharmacy Technician Specialty Pharmacies 
Pharmacy Times
JUNE 24, 2025
This is progressing through a phase 3 trial and includes comparator arms with standard-of-care treatments like daratumumab, bortezomib (Velcade; Millennium/Takeda and Janssen Pharmaceutical Companies), and lenalidomide. 2 We’re still trying to figure out where these new treatments best fit.
Pharmaceutical Commerce
JUNE 18, 2025
Asembia’s AXS25 Summit—held annually at both the Wynn and Encore in Las Vegas, NV—brings together thousands of pharmaceutical industry executives in hopes of continuing the conversation surrounding specialty pharmacy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 23, 2025
In 2022, based upon a complaint filed by a pharmaceutical company, CMS was asked to reevaluate the SSA section that establishes the J-code,” Soefje said. So, the pharmaceutical companies then pushed to get their 505(b)(2) drugs declared sole source,” Soefje said. “If This went into effect in January 2022.”
Pharmacy Times
JUNE 27, 2025
4,5 DREAMM-7 In DREAMM-7, patients with RRMM who had received at least 1 prior line of therapy were randomized 1:1 to receive belantamab mafodotin plus bortezomib (Velcade; Millennium/Takeda and Janssen Pharmaceutical Companies) and dexamethasone (BVd) compared with daratumumab (Darzalex; Johnson & Johnson), bortezomib, and dexamethasone (DVd).
Expert insights. Personalized for you.
Let's personalize your content